ArticleScience advances2026
Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinoma.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gamma delta (γδ) T cells are critical for tissue immune surveillance and their presence in tumors correlates with a favorable prognosis, highlighting their therapeutic potential. Although γδ T cells are abundant in the skin, their therapeutic value in skin cancer has remained largely unexplored due to challenges in isolating sufficient numbers of γδ T cells from human tissues and a lack of suitable preclinical models for skin cancer. Here, we are using innovative methods to expand human cutaneous γδ T cells ex vivo, enabling us to investigate their therapeutic potential in a human cutaneous squamous cell carcinoma (cSCC) mouse model. In this model, γδ T cells were specifically recruited to and maintained in the cSCC xenograft. These tumor-infiltrating cells exhibited an activated, cytotoxic phenotype and demonstrated effective antitumor activity in vivo. Collectively, our findings provide preclinical evidence supporting human skin-resident γδ T cells as a promising immunotherapeutic approach for treating skin cancers such as cSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.